Citi Pharma Balance Sheet

Financials in millions PKR. Fiscal year is July - June.

Millions PKR. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Cash & Equivalents	321.07	603.55	87.9	54.61	27.48	3,074
Short-Term Investments	3.12	919.59	1,222	1,393	1,660	-
Trading Asset Securities	-	66.5	108.81	132.36	312.12	-
Cash & Short-Term Investments	324.19	1,590	1,418	1,580	2,000	3,074
Cash Growth	-75.43%	12.08%	-10.26%	-20.97%	-34.96%	3337.25%
Accounts Receivable	4,217	3,078	2,197	1,882	1,402	444.55
Other Receivables	-	150.02	203.26	96.29	45.77	-
Receivables	4,217	3,228	2,400	1,978	1,447	444.55
Inventory	4,407	3,930	3,203	2,609	1,692	778.19
Other Current Assets	1,023	723.98	613.03	415.98	458.15	204.08
Total Current Assets	9,971	9,472	7,635	6,584	5,597	4,501
Property, Plant & Equipment	8,624	8,688	3,530	3,122	2,258	1,735
Long-Term Accounts Receivable	-	-	-	23.65	-	8.61
Other Long-Term Assets	282.33	279.98	274.76	254.54	272.06	254.54
Total Assets	18,878	18,439	11,439	9,984	8,127	6,499
Accounts Payable	3,599	3,479	3,374	1,938	1,618	993.58
Accrued Expenses	86.08	236.33	216.54	206.62	149.67	58.54
Short-Term Debt	3,420	2,869	1,437	1,768	521.57	12.2
Current Portion of Long-Term Debt	-	-	12.86	55.88	160.69	108.71
Current Portion of Leases	62.19	15.8	5.42	5.67	4.77	2.99
Current Income Taxes Payable	464.13	519.68	470.83	393.19	404.18	126.87
Current Unearned Revenue	-	-	0.58	3.04	14.51	5.86
Other Current Liabilities	2.5	185.89	83.03	82.1	137.28	526.77
Total Current Liabilities	7,633	7,305	5,599	4,453	3,010	1,836
Long-Term Debt	30.71	-	-	8.54	250.17	189.16
Long-Term Leases	53.21	64.86	-	4.37	6.27	7.76
Long-Term Unearned Revenue	-	-	-	0.58	32.17	9.27
Pension & Post-Retirement Benefits	-	99.7	82.62	50.34	31.94	14.25
Long-Term Deferred Tax Liabilities	208.73	102.07	124.09	94.24	82.3	77.17
Other Long-Term Liabilities	-	0	-	-	-	-0
Total Liabilities	7,926	7,572	5,806	4,611	3,413	2,133
Common Stock	2,285	2,285	2,285	2,285	2,285	1,350
Additional Paid-In Capital	1,392	1,392	1,392	1,392	1,392	-
Retained Earnings	1,891	1,807	1,648	1,388	728.54	380.61
Comprehensive Income & Other	5,385	5,385	309.29	309.29	309.29	2,635
Shareholders' Equity	10,951	10,868	5,633	5,373	4,714	4,366
Total Liabilities & Equity	18,878	18,439	11,439	9,984	8,127	6,499
Total Debt	3,566	2,950	1,455	1,843	943.48	320.81
Net Cash (Debt)	-3,242	-1,360	-36.55	-262.2	1,056	2,754
Net Cash Growth	-	-	-	-	-61.65%	-
Net Cash Per Share	-14.20	-5.95	-0.16	-1.15	4.66	14.77
Filing Date Shares Outstanding	227.62	228.46	228.46	228.46	228.46	148.5
Total Common Shares Outstanding	227.62	228.46	228.46	228.46	228.46	148.5
Working Capital	2,338	2,166	2,035	2,131	2,586	2,666
Book Value Per Share	48.11	47.57	24.66	23.52	20.63	29.40
Tangible Book Value	10,951	10,868	5,633	5,373	4,714	4,366
Tangible Book Value Per Share	48.11	47.57	24.66	23.52	20.63	29.40
Land	-	6,940	1,865	1,865	1,421	1,049
Buildings	-	673.95	661.56	485.03	309.33	214.96
Machinery	-	1,758	1,525	1,194	915.01	795.57
Construction In Progress	-	49.11	130.04	70.39	14.33	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.